Objective: To summarize the clinical characteristics of coronavirus disease 2019 (COVID-19) in patients with Good's syndrome. Methods: We included all cases of COVID-19 in patients with Good's syndrome in the Second Xiangya Hospital of Central South University from January 1, 2023 to August 31, 2023. In addition to our cases, we searched the published literature in Wanfang database and PubMed database using the keywords "Good's syndrome" and "COVID-19". The clinical characteristics, treatment and outcome of the patients were summarized and analyzed. Results: A total of four patients with Good's syndrome complicated by COVID-19 were identified in our hospital, all of them were male, and the days of hospitalization were 17, 23, 7, and 13 days, respectively. Databases were searched for a total of six patients with Good's syndrome complicated by COVID-19, including three females and three males, all foreign patients, with hospitalization days of 12, 22, 13, 25, 21, and 34 days respectively. All ten patients met the diagnostic criteria for severe or critical COVID-19, and three(all middle-aged males) of them died, two from sepsis and one from respiratory failure. They were. Conclusion: COVID-19 in patients with Good's syndrome are prone to develop severe or critical disease and are more likely to be infected with multiple pathogens. Timely immunoglobulin supplementation is the key to treatment.
目的： 总结和分析Good综合征合并2019冠状病毒病（COVID-19）患者的临床特点。 方法： 回顾性分析2023年1月1日至8月31日中南大学湘雅二医院诊治的4例Good综合征合并COVID-19患者的临床资料，并以“Good综合征”“新型冠状病毒”为关键词，检索万方数据库和PubMed数据库相关文献，对患者的临床特征、治疗与转归进行归纳分析。 结果： 本院4例Good综合征合并COVID-19患者均为男性，住院天数分别为17、23、7、13 d。数据库共检索到6例Good综合征合并COVID-19病例，均为国外患者，其中女性3例，男性3例，住院天数分别为12、22、13、25、21、34 d，10例患者均达到重症或危重症新冠肺炎诊断标准，其中3例患者死亡（2例患者死于脓毒血症，1例患者死于呼吸衰竭），均为中年男性患者。 结论： Good综合征患者合并COVID-19易发展为重症或危重症新冠肺炎，且更易合并多种病原体混合感染，及时补充免疫球蛋白是治疗的关键。.